|
Reliant Pharmaceuticals gets to the heart of the matter. The company markets controlled-release treatments for various cardiovascular ailments. Rather than go through the time and expense of developing drugs from start to finish in its own labs, the drugmaker instead buys rights to already-approved or late-stage development pharmaceuticals. Reliant's portfolio of cardiovascular drugs includes omega-3 product Lovaza, which combats high triglycerides (fatty substances that may cause coronary heart disease); high blood-pressure meds InnoPran XL and DynaCirc; and irregular heart-rhythm treatment Rhythmol SR. Reliant Pharmaceuticals was acquired by GlaxoSmithKline (GSK) for $1.65 billion in 2007.
|
| | | Contact Information | |
Address: |
110 Allen Rd.
Liberty Corner, NJ 07938
| | Phone: | 908-580-1200 | | Fax: | 908-542-9405 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2006): | 367.50 M | | Revenue Growth (1 yr): | 67.30% | | Employees (2006): | 1,000 |
|
|
Key People
| | • |
Chairman:
Frederick B. (Fred) Craves
| | • |
CFO:
Robert R. (Bob) Ferguson III
| | • |
SVP Sales and Marketing:
Vincent J. Angotti
|
|
|
